newdeal®
An Integra LifeSciences Company

510(K) SUMMARY

Lisfranc Plates

FEB 8 2007

Submitter's name and address:
Newdeal SAS
10, place d'Helvétie
69006 Lyon, France
Tel: +33 4 37 47 51 51
Fax: +33 4 37 47 51 52

Contact person and telephone number
Morgane Grenier
Regulatory and Clinical Affairs Director
Newdeal SAS
10, place d'Helvétie
69006 Lyon, France
Tel: +33 4 37 47 51 51
Fax: +33 4 37 47 51 52

Alternate Contacts
Authorized Agent in the United States
Judith E. O'Grady, RN, MSN
Sr. Vice President, Regulatory Affairs, Quality Assurance and Clinical Affairs
Integra LifeSciences Corporation
311 Enterprise Drive
Plainsboro, NJ 08536, USA
Tel: (609) 936-2311
Fax: (609) 275-9445
E-mail: jogrady@integra-ls.com

Date Summary was prepared:
December 22, 2006.

Name of the device:

Proprietary Name:	Lisfranc Plate
Common Name:	Plate, Fixation, Bone
Classification Name:	Single/multiple component metallic bone fixation appliances and accessories (21CFR 888.3030)
Device Product Code:	HRS
Classification Panel:	Orthopedic

Substantial Equivalence:
The modified Lisfranc Plates (with stainless steel locking system) are substantially equivalent to commercially marketed device, Lisfranc Plates, K060474.

Device Description:
The NEWDEAL® Lisfranc Plate consists of an osteosynthesis plate designed to bridge the tarsometatarsal joints (Lisfranc joints). It is available in different sizes, and is implanted using NEWDEAL® locking system fixation screws and washers. The NEWDEAL® locking system includes as many fixation screws as there are threaded lipped sockets on the plate and as many washers as

implanted screws. The NEWDEAL® locking system creates a single implant/screw unit fixed into the bone. The osteosynthesis screws must be driven into the bone through the holes in the plate. The system is locked by means of washers drilled into the threaded lipped socket at the top of each hole, thus blocking each screw head.

Intended Use:
The Newdeal Lisfranc Plates are intended for fractures, fusions, osteotomies and replantations of small bones at the tarsometarsal joints (Lisfranc joints).

Testing and Test Results:
Mechanical tests have been carried out. Results have shown that the mechanical properties of the modified LISFRANC PLATES are thus similar to the properties of the unmodified device, Lisfranc Plates, K060474.

Conclusion
The modified Lisfranc Plates (with stainless steel locking system) are substantially equivalent to commercially marketed device, Lisfranc Plates, K060474.

The modifications do not change the intended use or fundamental scientific technology of the device and do not raise any new issues of safety or effectiveness.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Newdeal SAS
% Judith O'Grady, R.N., M.S.N.
Senior Vice President, Regulatory Affairs
Integra Lifesciences Corporation
311 Enterprise Drive
Plainsboro, New Jersey 08536

FEB 9 2007

Re: K063820
Trade/Device Name: Lisfranc Plate
Regulation Number: 21 CFR 888.3030
Regulation Name: Single/multiple component metallic bone fixation appliances and accessories
Regulatory Class: II
Product Code: HRS
Dated: February 2, 2007
Received: February 5, 2007

Dear Ms. O'Grady:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Mark N. Melkerson
Director
Division of General, Restorative
and Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

Indications for Use

510(k) Number (if known): K063820

Device Name: Lisfranc Plates

Indications For Use:
The Newdeal Lisfranc Plates are intended for fractures, fusions, osteotomies and replantations of small bones at the tarsometarsal joints (Lisfranc joints).

Prescription Use ___X___ (Part 21 CFR 801 Subpart D) AND/OR Over-The-Counter Use _____ (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Barbara Ruehr

(Division Sign-Off)
Division of General, Restorative, and Neurological Devices

510(k) Number K063820